XPLN is modulated by HDAC inhibitors and negatively regulates SPARC expression by targeting mTORC2 in human lung fibroblasts.
Kamio K, Azuma A, Usuki J, Matsuda K, Inomata M, Nishijima N, Itakura S, Hayashi H, Kashiwada T, Kokuho N, et al. Pulm Pharmacol Ther. 2017 Jun; 44:61-69. Epub 2017 Mar 14.